New data from two large studies presented at the 2025 ASCO Gastrointestinal Cancers Symposium (GICS) 2025 provide evidence of the clinical utility of circulating tumor DNA (ctDNA) testing in ...

Desai, MBBS, MD, assistant professor of thoracic medical oncology/head and neck medical oncology at Fox Chase Cancer Center ...

Circulating tumor DNA (ctDNA) can be detected in plasma samples sometimes several years prior to a clinical diagnosis of cancer, according to research ...

Dr. Alan Tan explores circulating tumor DNA, its role in clinical trials and its potential impact on patients with renal cell carcinoma. Circulating tumor DNA (ctDNA) is not yet standard practice in ...

ctDNA testing could help doctors track response, reduce unnecessary chemo, and identify relapse early for patients with aggressive B cell lymphomas. Dr. Hua-Jay Cherng, a hematologist oncologist at ...

SAN FRANCISCO -- Circulating tumor DNA (ctDNA) measurements showed promise for identifying patients with early colorectal cancer (CRC) most likely to benefit from adjuvant therapy, analyses of two ...

Joanne Mortimer, MD, FACP, FASCO, discusses the practical applications and limitations of circulating tumor DNA (ctDNA) testing in breast cancer, highlighting its role in guiding targeted therapy, ...

Angus Chen covers all issues broadly related to cancer including drugs, policy, science, and equity. He joined STAT in 2021 after covering health and science at NPR and NPR affiliate stations. His ...

For years, breast cancer treatment has been guided by genetic alterations found in tumor tissue, typically through invasive biopsies. However, the dynamic nature of cancer and limitations in tissue ...

A data analysis from a randomized clinical trial for stage 3 colon cancer patients by investigators at Dana-Farber Brigham Cancer Center found that patients with evidence of residual cancer in their ...

Of the patients who were initially ctDNA positive and received pembrolizumab, 85% had ctDNA clearance at 6 months. “The study suggests that ctDNA-guided treatment strategies may help prevent relapse ...

Quest Diagnostics (NYSE:DGX) announced a US$500 million senior notes offering. The company also entered a multi year clinical partnership with City of Hope focused on advanced ctDNA testing. The ...